The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
Articles by Marisa Wexler, MS
Ultomiris (ravulizumab) is safe and results in stable kidney and blood measurements in children and adolescents with atypical…
Soliris (eculizumab) can meaningfully ease fatigue and other symptoms commonly reported by people with atypical hemolytic uremic syndrome (aHUS),…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
Research is needed to identify more mutations that cause atypical hemolytic uremic syndrome (aHUS), as well as to establish…
The Committee for Medicinal Products for Human Use (CHMP) has recommended that a new 100 mg/mL advanced formulation of…
Researchers have identified a novel mutation in the gene DGKE that can cause atypical hemolytic uremic syndrome (aHUS)…
Soliris (eculizumab) is safe and effective for the prevention of recurrence in people with atypical hemolytic uremic…
Atypical hemolytic uremic syndrome (aHUS) can co-exist with autoimmune disorders, complicating the diagnosis of the rare blood-clotting disease,…
A rare type of inflammatory arthritis known as Still’s disease may trigger the development of atypical hemolytic uremic…